Developer docs
API playgroundTry for free, no card

Search company profiles

Addex Therapeutics

Full company profile

uuid0002klu

Namestring
Addex Therapeutics
Legal namestring
Addex Therapeutics Ltd
Company typeenum
Public
Founded yearint
2002
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPlan-les-ouates, Switzerland
HQ citystring
Plan-les-ouates
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
allosteric modulator drugs, neurological disorder therapies, small molecule therapeutics, CNS drug development, biopharmaceutical drug discovery
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurological Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Partnership milestone payments
TypeLicensing Royalties
Description

Addex receives milestone payments upon successful achievement of prespecified regulatory, clinical and commercial milestones from partners. For the GABAB PAM substance use disorder program with Indivior, Addex is eligible for payments up to USD 330 million plus tiered royalties on net sales from high single digits up to low double-digit.

addextherapeutics.com
2Royalty revenue
TypeLicensing Royalties
Description

Tiered royalties on net sales from commercialized products developed by partners, currently in development stage with no commercialized products generating revenue yet.

addextherapeutics.com
3Research collaboration funding
TypeProfessional Services
Description

Funding received from partners for research activities, including CHF 2.7 million from Indivior for GABAB PAM substance use disorder research collaboration extended until June 2024.

startupticker.ch
4Grant funding
TypeProfessional Services
Description

Eurostars grant funding of €4 million for mGlu2 NAM program targeting mild neurocognitive disorder (COGNI+ project).

globenewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Addex Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops orally available small molecule allosteric modulators—both Positive Allosteric Modulators (PAMs) and Negative Allosteric Modulators (NAMs)—for the treatment of neurological and psychiatric disorders. The company's portfolio includes dipraglurant (mGlu5 NAM) for post-stroke and traumatic brain injury recovery, ADX71149 (mGlu2 PAM), partnered GABAB PAM programs for substance use disorder (Indivior) and chronic cough, and the muscarinic M4 PAM NTX-253 advanced via its Neurosterix spin-out for schizophrenia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • GABAB PAM demonstrated robust anti-tussive activity in non-human primate chronic cough model with efficacy similar to baclofen but better tolerability
+3 more records
Product overview1 text field

Addex Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of novel small molecule allosteric modulators for neurological disorders. The company's core technology platform focuses on allosteric modulation, which offers advantages over traditional orthosteric drugs by providing greater selectivity and better modulatory control at disease-mediating receptors. The product portfolio includes: Dipraglurant (mGlu5 NAM) in development for post-stroke and traumatic brain injury recovery; ADX71149 (mGlu2 PAM) with rights recently regained for potential future development; a partnered GABAB PAM program with Indivior for substance use disorders; and an independent GABAB PAM program for chronic cough. Additionally, Addex holds a 20% equity interest in Neurosterix LLC, which is advancing NTX-253 (M4 PAM) for schizophrenia through Phase 1 studies.

Product and service5 records
1Dipraglurant (mGlu5 NAM)
CategoryClinical-stage small molecule drug candidate
Description

A metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) being developed for post-stroke sensorimotor recovery and traumatic brain injury recovery, intended for patients with neurological disorders where current therapies rely on retraining and physiotherapy with partial recovery taking six months or more.

2ADX71149 (mGlu2 PAM)
CategoryClinical-stage small molecule drug candidate
Description

A positive allosteric modulator of metabotropic glutamate receptor subtype 2, previously partnered for an epilepsy Phase 2a study, with rights recently regained by Addex for potential future development in CNS indications.

3GABAB PAM - Substance Use Disorder Program
CategoryPartnered clinical-stage drug candidate
Description

A gamma-aminobutyric acid subtype B receptor positive allosteric modulator (GABAB PAM) program partnered with Indivior PLC for substance use disorders, with Addex eligible for up to USD 330 million in milestone payments plus tiered royalties from high single digits to low double-digit on net sales.

4GABAB PAM - Chronic Cough Program
CategoryPreclinical-stage drug candidate
Description

An independent GABAB positive allosteric modulator program being developed by Addex for the treatment of chronic cough, including in idiopathic pulmonary fibrosis (IPF), aiming to deliver a best-in-class therapy with improved tolerability compared with off-label baclofen.

5NTX-253 (M4 PAM)
CategorySpin-out clinical-stage drug candidate (Neurosterix)
Description

A potent, selective, orally available positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia treatment, targeting dopamine signaling indirectly to avoid the metabolic, cognitive, and motor side effects of dopamine-receptor antipsychotics. Advanced by Neurosterix, in which Addex holds 20% equity.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Addex entered option and collaboration agreement with Sinntaxis AB for exclusive license to intellectual property covering use of mGlu5 inhibitors for treatment of brain injury recovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-02
Description

Spin-out company advancing portfolio of allosteric modulator programs including M4 PAM for schizophrenia (NTX-253 in Phase 1) and mGlu7 NAM for mood disorders. Addex retains 20% equity interest. Neurosterix raised $65 million Series A (led by Perceptive Advisors).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-30
Description

Indivior holds worldwide rights to Addex's GABAB PAM program for addiction and is responsible for all development, manufacture and commercialization. Addex retains rights for indications outside addiction including cough, pain. Indivior has selected a GABAB PAM candidate and successfully completed IND enabling studies. Addex eligible for up to USD 330 million in milestones plus tiered royalties from high single digits to low double digits.

4COGNI+ Consortium (Eurostars)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-20
Description

Led consortium receiving €4 million Eurostars grant for mGlu2 NAM program targeting mild neurocognitive disorder (mNCD). Partners from South Korea, Netherlands, and UK. Project aims to deliver clinical candidates for IND enabling studies.

globenewswire.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to characterize and better understand effects of allosteric modulators of metabotropic glutamate receptors.

6University of Pavia / Mondino Foundation (Prof. Antonio Pisani)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to explore use of dipraglurant to treat rare genetic forms of dystonia, evaluating effects of chronic treatment in preclinical models.

addextherapeutics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to evaluate pharmacology of GABAB receptor positive allosteric modulators in preclinical models of visceral pain during urinary bladder inflammation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to evaluate efficacy of GABAB receptor positive allosteric modulators in preclinical model of CMT1A, a rare peripheral neuropathy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

NIAAA collaborating with Addex to evaluate pharmacology of positive and negative allosteric modulators in preclinical models of alcohol use disorder.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

NIDA collaborating to evaluate allosteric modulators in preclinical models of drug abuse and addiction. Program received USD 5.3 million grant to fund Phase 1 and Phase 1b cocaine interaction study.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Swiss Innovation Agency providing grants to support Addex projects in collaboration with CHUV, University of Geneva, and Swiss Institute of Bioinformatics.

12The Michael J Fox Foundation for Parkinson's Research
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Awarded $1.8 million grant to fund continued clinical testing of dipraglurant for treatment of Parkinson's disease levodopa-induced dyskinesia.

addextherapeutics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to explore use of dipraglurant to treat dystonia, designing detailed development plan and regulatory path for Phase 2 clinical trial.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to evaluate GABAB receptor PAMs in preclinical models of Charcot-Marie-Tooth 1A disorder.

15Swiss Institute of Bioinformatics (SIB)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration to apply computational approaches including AI, deep learning and molecular modelling to identify new therapeutic indications for ADX10061.

addextherapeutics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cerevel (acquired by AbbVie in 2024) developed positive allosteric modulators of muscarinic M4 receptors for schizophrenia — directly overlapping with Addex's NTX-253 M4 PAM program now at Neurosterix. Both pursue allosteric strategies targeting CNS GPCRs.

TypeDirect peer
Description

Karuna (acquired by BMS) developed xanomeline, an M1/M4 muscarinic agonist for schizophrenia, advancing the same receptor family as Addex's M4 PAM. Both target CNS muscarinic signaling via alternative mechanistic angles for schizophrenia.

TypeDirect peer
Description

Sage develops novel CNS small molecules (GABA-A receptor modulators like Zurzuvae for depression). Directly comparable as a clinical-stage CNS biotech pursuing differentiated receptor modulation approaches.

TypeBroad incumbent
Description

Acadia is a commercial CNS specialty pharma with Nuplazid approved for Parkinson's disease psychosis — overlapping with Addex's dipraglurant Parkinson's levodopa-induced dyskinesia program. Acadia has deeper commercial CNS infrastructure and broader pipeline.

TypeBroad incumbent
Description

Intra-Cellular (acquired by J&J) developed Caplyta for schizophrenia and other CNS therapies. Comparable as a CNS-focused biopharma with novel mechanisms addressing psychiatric disorders — overlapping with Addex's schizophrenia and mood disorder programs.

TypeDirect peer
Description

Axsome is a CNS-focused commercial-stage biopharma with Auvelity for depression and other CNS pipeline programs. Comparable in clinical-stage CNS focus targeting underserved neurological and psychiatric indications.

TypeDirect peer
Description

Biohaven develops CNS therapies including CGRP-targeting agents for migraine and other neuroscience pipeline programs. Comparable as a CNS-focused clinical-to-commercial stage biopharma targeting neurological conditions.

TypeEmerging player
Description

Tonix is a clinical-stage CNS biopharma focused on neurological and psychiatric disorders including PTSD, depression and chronic pain — directly overlapping with Addex's mGlu7 NAM PTSD/anxiety program.

9Mind Medicine (MindMed)
TypeEmerging player
Description

MindMed is a clinical-stage neuropsychiatry company developing psychedelic-inspired therapies for anxiety, ADHD and substance use disorders. Overlaps with Addex's GABAB PAM substance use disorder and mGlu7 NAM anxiety programs.

TypeEmerging player
Description

Neumora is a clinical-stage neuroscience company developing precision therapies for brain diseases including depression and schizophrenia. Comparable as a well-funded CNS biotech pursuing novel mechanisms in overlapping indications with Addex's pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds21 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Addex Therapeutics

Neurological Therapeuticsaddextherapeutics.com

Addex Therapeutics firmographics

Firmographics
Name
Addex Therapeutics
Legal name
Addex Therapeutics Ltd
Website
https://addextherapeutics.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Addex Therapeutics industry classification

Industry
Product category
Neurological Therapeutics
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Allosteric modulator drugs
  • Neurological disorder therapies
  • Small molecule therapeutics
  • CNS drug development
  • Biopharmaceutical drug discovery

Where Addex Therapeutics is headquartered

Location

Headquarters

HQ city
Plan-les-ouates
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Addex Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Partnership milestone payments: Addex receives milestone payments upon successful achievement of prespecified regulatory, clinical and commercial milestones from partners. For the GABAB PAM substance use disorder program with Indivior, Addex is eligible for payments up to USD 330 million plus tiered royalties on net sales from high single digits up to low double-digit.
  2. Royalty revenue: Tiered royalties on net sales from commercialized products developed by partners, currently in development stage with no commercialized products generating revenue yet.
  3. Research collaboration funding: Funding received from partners for research activities, including CHF 2.7 million from Indivior for GABAB PAM substance use disorder research collaboration extended until June 2024.
  4. Grant funding: Eurostars grant funding of €4 million for mGlu2 NAM program targeting mild neurocognitive disorder (COGNI+ project).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Addex Therapeutics product offering

Product offering

Core offering

Addex Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops orally available small molecule allosteric modulators—both Positive Allosteric Modulators (PAMs) and Negative Allosteric Modulators (NAMs)—for the treatment of neurological and psychiatric disorders. The company's portfolio includes dipraglurant (mGlu5 NAM) for post-stroke and traumatic brain injury recovery, ADX71149 (mGlu2 PAM), partnered GABAB PAM programs for substance use disorder (Indivior) and chronic cough, and the muscarinic M4 PAM NTX-253 advanced via its Neurosterix spin-out for schizophrenia.

Product overview

Addex Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of novel small molecule allosteric modulators for neurological disorders. The company's core technology platform focuses on allosteric modulation, which offers advantages over traditional orthosteric drugs by providing greater selectivity and better modulatory control at disease-mediating receptors. The product portfolio includes: Dipraglurant (mGlu5 NAM) in development for post-stroke and traumatic brain injury recovery; ADX71149 (mGlu2 PAM) with rights recently regained for potential future development; a partnered GABAB PAM program with Indivior for substance use disorders; and an independent GABAB PAM program for chronic cough. Additionally, Addex holds a 20% equity interest in Neurosterix LLC, which is advancing NTX-253 (M4 PAM) for schizophrenia through Phase 1 studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dipraglurant (mGlu5 NAM) A metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) being developed for post-stroke sensorimotor recovery and traumatic brain injury recovery, intended for patients with neurological disorders where current therapies rely on retraining and physiotherapy with partial recovery taking six months or more.
  • ADX71149 (mGlu2 PAM) A positive allosteric modulator of metabotropic glutamate receptor subtype 2, previously partnered for an epilepsy Phase 2a study, with rights recently regained by Addex for potential future development in CNS indications.
  • GABAB PAM - Substance Use Disorder Program A gamma-aminobutyric acid subtype B receptor positive allosteric modulator (GABAB PAM) program partnered with Indivior PLC for substance use disorders, with Addex eligible for up to USD 330 million in milestone payments plus tiered royalties from high single digits to low double-digit on net sales.
  • GABAB PAM - Chronic Cough Program An independent GABAB positive allosteric modulator program being developed by Addex for the treatment of chronic cough, including in idiopathic pulmonary fibrosis (IPF), aiming to deliver a best-in-class therapy with improved tolerability compared with off-label baclofen.
  • NTX-253 (M4 PAM) A potent, selective, orally available positive allosteric modulator of the muscarinic M4 receptor being developed for schizophrenia treatment, targeting dopamine signaling indirectly to avoid the metabolic, cognitive, and motor side effects of dopamine-receptor antipsychotics. Advanced by Neurosterix, in which Addex holds 20% equity.

Quantifiable outcome

  • GABAB PAM demonstrated robust anti-tussive activity in non-human primate chronic cough model with efficacy similar to baclofen but better tolerability
  • +3 more outcomes

Companies that use Addex Therapeutics

Customer profile

Segments5 records

Ideal customer profiles3 records

Addex Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Addex Therapeutics partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and minor.

  • Sinntaxis ABcoreStrategic or Co-development Partner · 1 January 2025Addex entered option and collaboration agreement with Sinntaxis AB for exclusive license to intellectual property covering use of mGlu5 inhibitors for treatment of brain injury recovery.
  • Neurosterix LLCcoreStrategic or Co-development Partner · 2 April 2024Spin-out company advancing portfolio of allosteric modulator programs including M4 PAM for schizophrenia (NTX-253 in Phase 1) and mGlu7 NAM for mood disorders. Addex retains 20% equity interest. Neurosterix raised $65 million Series A (led by Perceptive Advisors).
  • Indivior PLCcoreStrategic or Co-development Partner · 30 January 2024Indivior holds worldwide rights to Addex's GABAB PAM program for addiction and is responsible for all development, manufacture and commercialization. Addex retains rights for indications outside addiction including cough, pain. Indivior has selected a GABAB PAM candidate and successfully completed IND enabling studies. Addex eligible for up to USD 330 million in milestones plus tiered royalties from high single digits to low double digits.
  • COGNI+ Consortium (Eurostars)minorStrategic or Co-development Partner · 20 September 2023Led consortium receiving €4 million Eurostars grant for mGlu2 NAM program targeting mild neurocognitive disorder (mNCD). Partners from South Korea, Netherlands, and UK. Project aims to deliver clinical candidates for IND enabling studies.
  • Neuromed (Prof. Ferdinando Nicoletti & Dr Giuseppe Battaglia)minorStrategic or Co-development PartnerCollaboration to characterize and better understand effects of allosteric modulators of metabotropic glutamate receptors.
  • University of Pavia / Mondino Foundation (Prof. Antonio Pisani)minorStrategic or Co-development PartnerCollaboration to explore use of dipraglurant to treat rare genetic forms of dystonia, evaluating effects of chronic treatment in preclinical models.
  • Medical College of Wisconsin (Prof. Jyoti Sengupta)minorStrategic or Co-development PartnerCollaboration to evaluate pharmacology of GABAB receptor positive allosteric modulators in preclinical models of visceral pain during urinary bladder inflammation.
  • Max Planck Institute (Prof. Michael Sereda)minorStrategic or Co-development PartnerCollaboration to evaluate efficacy of GABAB receptor positive allosteric modulators in preclinical model of CMT1A, a rare peripheral neuropathy.
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)minorStrategic or Co-development PartnerNIAAA collaborating with Addex to evaluate pharmacology of positive and negative allosteric modulators in preclinical models of alcohol use disorder.
  • National Institute on Drug Abuse (NIDA)minorStrategic or Co-development PartnerNIDA collaborating to evaluate allosteric modulators in preclinical models of drug abuse and addiction. Program received USD 5.3 million grant to fund Phase 1 and Phase 1b cocaine interaction study.
  • Innosuisse (Swiss Innovation Agency)minorStrategic or Co-development PartnerSwiss Innovation Agency providing grants to support Addex projects in collaboration with CHUV, University of Geneva, and Swiss Institute of Bioinformatics.
  • The Michael J Fox Foundation for Parkinson's ResearchminorStrategic or Co-development PartnerAwarded $1.8 million grant to fund continued clinical testing of dipraglurant for treatment of Parkinson's disease levodopa-induced dyskinesia.
  • Dystonia Medical Research FoundationminorStrategic or Co-development PartnerCollaboration to explore use of dipraglurant to treat dystonia, designing detailed development plan and regulatory path for Phase 2 clinical trial.
  • Charcot Marie Tooth Association (CMTA)minorStrategic or Co-development PartnerCollaboration to evaluate GABAB receptor PAMs in preclinical models of Charcot-Marie-Tooth 1A disorder.
  • Swiss Institute of Bioinformatics (SIB)minorStrategic or Co-development PartnerCollaboration to apply computational approaches including AI, deep learning and molecular modelling to identify new therapeutic indications for ADX10061.

Scale indicators14 records

Recent moves7 records

Expansion highlights5 records

Addex Therapeutics competitors and assessment

Company assessment

Direct peers

  • Cerevel Therapeutics: Cerevel (acquired by AbbVie in 2024) developed positive allosteric modulators of muscarinic M4 receptors for schizophrenia — directly overlapping with Addex's NTX-253 M4 PAM program now at Neurosterix. Both pursue allosteric strategies targeting CNS GPCRs.
  • Karuna Therapeutics: Karuna (acquired by BMS) developed xanomeline, an M1/M4 muscarinic agonist for schizophrenia, advancing the same receptor family as Addex's M4 PAM. Both target CNS muscarinic signaling via alternative mechanistic angles for schizophrenia.
  • Sage Therapeutics: Sage develops novel CNS small molecules (GABA-A receptor modulators like Zurzuvae for depression). Directly comparable as a clinical-stage CNS biotech pursuing differentiated receptor modulation approaches.
  • Axsome Therapeutics: Axsome is a CNS-focused commercial-stage biopharma with Auvelity for depression and other CNS pipeline programs. Comparable in clinical-stage CNS focus targeting underserved neurological and psychiatric indications.
  • Biohaven Pharmaceutical: Biohaven develops CNS therapies including CGRP-targeting agents for migraine and other neuroscience pipeline programs. Comparable as a CNS-focused clinical-to-commercial stage biopharma targeting neurological conditions.

Broad incumbents

  • Acadia Pharmaceuticals: Acadia is a commercial CNS specialty pharma with Nuplazid approved for Parkinson's disease psychosis — overlapping with Addex's dipraglurant Parkinson's levodopa-induced dyskinesia program. Acadia has deeper commercial CNS infrastructure and broader pipeline.
  • Intra-Cellular Therapies: Intra-Cellular (acquired by J&J) developed Caplyta for schizophrenia and other CNS therapies. Comparable as a CNS-focused biopharma with novel mechanisms addressing psychiatric disorders — overlapping with Addex's schizophrenia and mood disorder programs.

Emerging players

  • Tonix Pharmaceuticals: Tonix is a clinical-stage CNS biopharma focused on neurological and psychiatric disorders including PTSD, depression and chronic pain — directly overlapping with Addex's mGlu7 NAM PTSD/anxiety program.
  • Mind Medicine (MindMed): MindMed is a clinical-stage neuropsychiatry company developing psychedelic-inspired therapies for anxiety, ADHD and substance use disorders. Overlaps with Addex's GABAB PAM substance use disorder and mGlu7 NAM anxiety programs.
  • Neumora Therapeutics: Neumora is a clinical-stage neuroscience company developing precision therapies for brain diseases including depression and schizophrenia. Comparable as a well-funded CNS biotech pursuing novel mechanisms in overlapping indications with Addex's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Addex Therapeutics social profiles

Digital presence

Addex Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Addex Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Addex Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Addex Therapeutics funding detail

Funding detail

Funding overview

Funding rounds21 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Addex Therapeutics M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Addex Therapeutics

What does Addex Therapeutics do?

Addex Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops orally available small molecule allosteric modulators—both Positive Allosteric Modulators (PAMs) and Negative Allosteric Modulators (NAMs)—for the treatment of neurological and psychiatric disorders. The company's portfolio includes dipraglurant (mGlu5 NAM) for post-stroke and traumatic brain injury recovery, ADX71149 (mGlu2 PAM), partnered GABAB PAM programs for substance use disorder (Indivior) and chronic cough, and the muscarinic M4 PAM NTX-253 advanced via its Neurosterix spin-out for schizophrenia.

Is Addex Therapeutics a public or private company?

Addex Therapeutics is a public company. It is classified as public and is currently operating.

When was Addex Therapeutics founded?

Addex Therapeutics was founded in 2002. It employs 11 to 50 people.

Where is Addex Therapeutics based?

Addex Therapeutics is headquartered in Plan-les-ouates, Switzerland, in the Europe region.

How does Addex Therapeutics make money?

Four revenue lines are on record. Partnership milestone payments are the primary driver. The others are royalty revenue, research collaboration funding and grant funding.

Who are Addex Therapeutics's main competitors?

Direct peers on record are Cerevel Therapeutics, Karuna Therapeutics, Sage Therapeutics, Axsome Therapeutics and Biohaven Pharmaceutical. Broad incumbents are Acadia Pharmaceuticals and Intra-Cellular Therapies. Emerging players are Tonix Pharmaceuticals, Mind Medicine (MindMed) and Neumora Therapeutics.

Does Addex Therapeutics have an API?

No public API is recorded for Addex Therapeutics.

What industry is Addex Therapeutics in?

Addex Therapeutics's product category is Neurological Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAddex Therapeutics (APE) Spin-Out Raises $105M; Addex Holds 8.5% Stake Valued at $18.6MNeurosterix, Addex's spin-out, closed a $105M Series B financing, with Addex not participating. Addex's 8.5% stake is valued at $18.6M, and proceeds will mainly support planned Phase 2 development of NTX-253.YahooADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARESAddex Therapeutics issued 93,000,000 new registered shares to its wholly-owned subsidiary Addex Pharma S.A., increasing issued share capital to CHF 3,116,544.96. The shares are listed on the SIX Swiss Exchange, and the transaction provides additional future financing flexibility.FinancialContent Business PageADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARESAddex Therapeutics issued 93 million new registered shares to its wholly-owned subsidiary Addex Pharma S.A., increasing issued share capital to CHF 3,116,544.96. The shares are listed on the SIX Swiss Exchange, and the transaction provides additional future financing flexibility.Ticker ReportAddex Therapeutics (NASDAQ:ADXN) & Takeda Pharmaceutical (NYSE:TAK) Head-To-Head AnalysisTakeda Pharmaceutical and Addex Therapeutics are compared across analyst ratings, institutional ownership, volatility, and profitability. Takeda beats Addex on 8 of 13 factors, with Takeda's beta of -0.07 versus Addex's 1.52, and Addex trading at a lower P/E ratio.Markets DailyClene (NASDAQ:CLNN) vs. Addex Therapeutics (NASDAQ:ADXN) Financial ComparisonClene and Addex Therapeutics are compared on financial metrics, analyst ratings, and ownership. Clene beats Addex on 8 of 14 factors, with a consensus price target of $34.00 implying 804.26% upside. Clene's lower beta and higher institutional ownership are also noted.Defense WorldAddex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Stock Short Interest Jumps 589.1%Short interest in Addex Therapeutics' ADR surged 589.1% to 1,840 shares as of September 30th. The stock opened at $3.11, and the company reported a quarterly loss of $1.48 per share. Analysts have a consensus "Sell" rating.American Banking and Market NewsAddex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Stock Short Interest Report for SeptemberAddex Therapeutics' short interest rose 589.1% to 1,840 shares as of September 30th, while the stock fell 2.2% to $3.11. The company reported a quarterly loss of $1.48 per share, and Weiss Ratings reissued a sell rating.FinancialContent Business PageAddex Therapeutics Announces Executive Management ChangesAddex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and member of Executive Management, and Mikhail Kalinichev stepped down as Head of Translational Science to focus on his role at Neurosterix. Rocher returns after retiring from Neurosterix, bringing over 30 years of drug discovery experience. The company is advancing its pipeline following regaining rights to its GABAB PAM program from Indivior.BioSpaceAddex Therapeutics Announces Executive Management ChangesAddex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and member of Executive Management, and Mikhail Kalinichev stepped down as Head of Translational Science to focus on Neurosterix. Rocher returns after retiring from Neurosterix, bringing experience in allosteric modulation and prior roles at Addex and Neurosterix.YahooAddex Therapeutics Ltd (ADXN) (Q2 2026) Earnings Call Highlights: Regained GABAB PAM Rights and ...Addex Therapeutics reported an operating loss of $1.1 million in H1 2026, down from $1.3 million, and a net loss of $3.4 million. The company raised $2.8 million via ATM facility, extending cash runway to Q4 2027, and regained full rights to its GABAB PAM program from Indivior. The SUD candidate is IND-ready, with the cough program awaiting financing.